{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:30:33Z","timestamp":1779114633214,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Domperidone (DOM) is a BCS class II drug which widely used as an oral medication for the control of nausea and vomiting. It showed a very low and variable bioavailability related to its very poor solubility and pre-systemic metabolism. Polymeric nanofibers (PNFs) exhibit unique properties that make them a favorable choice for drug delivery applications. The study aimed to develop an optimum fast-dissolving oral polymeric electrospun nanofiber of DOM using Eudragit L100\/Polyvinyl alcohol (EL-100\/PVA) polymer blend. The fabrication process was optimized through a set of formulation parameters (composition of the polymer blend, polymer blend concentration, and electrospinning voltage). The DOM-loaded EL-100\/PVA NFs were characterized for surface shape, nanosize, % drug loading, DOM in vitro release, drug\/polymer interaction, and in vivo prokinetic study. The optimization process showed defect-free DOM-loaded NFs with very low nano diameter, high DOM loading, and superior in vitro dissolution of DOM at intestinal pH (about 90% of the drug released within 5\u00a0min). The drug\/polymer interaction study demonstrated the conversion of DOM into an amorphous form, which facilitated its dissolution. No physicochemical interaction between DOM and the polymer blend was observed. I\n                    <jats:italic>n vivo<\/jats:italic>\n                    prokinetic study signified the orally enhanced prokinetic activity of DOM-loaded NF relative to pure DOM and commercial DOM product. The DOM-loaded EL-100\/PVA NFs exhibited a better effect on the gastrointestinal reactivity relative to free DOM and commercial DOM product. The superior in vitro dissolution and in vivo prokinetic activity proved the promising potential of polymeric NFs to improve the oral delivery of DOM. The optimized DOM-loaded EL-100\/PVA NFs may allow for dose reduction and low cardiovascular risk compared to conventional DOM tablets.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-025-01995-6","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:51:59Z","timestamp":1762447919000},"page":"1966-1980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design and preparation of novel domperidone loaded polymeric blend electrospun nanofibers for improved oral pharmacodynamic activity"],"prefix":"10.1007","volume":"16","author":[{"given":"Kamal","family":"Shatla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Sweed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleiman","family":"Eltokhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel Hamid","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour Abd","family":"El-Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El-Refaie","family":"Kenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-1713","authenticated-orcid":false,"given":"Yusuf","family":"Haggag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.matchemphys.2008.07.081","volume":"113","author":"E-R Kenawy","year":"2009","unstructured":"Kenawy E-R, Abdel-Hay FI, El-Newehy MH, Wnek GE. Processing of polymer nanofibers through electrospinning as drug delivery systems. Mater Chem Phys. 2009;113:296\u2013302.","journal-title":"Mater Chem Phys"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"106241","DOI":"10.1016\/j.jddst.2024.106241","volume":"101","author":"YA Haggag","year":"2024","unstructured":"Haggag YA, Abdel-Wahab M, Eltokhy SS, Elnawasany S, Mabrouk MM, Kenawy E-R. Co-delivery of novel valsartan and hydrochlorothiazide pH-responsive electrospun polymeric nanofibers for improved oral delivery. J Drug Deliv Sci Technol. 2024;101:106241.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1995_CR3","doi-asserted-by":"publisher","first-page":"014108","DOI":"10.1088\/1468-6996\/11\/1\/014108","volume":"11","author":"W Cui","year":"2010","unstructured":"Cui W, Zhou Y, Chang J. Electrospun nanofibrous materials for tissue engineering and drug delivery. Sci Technol Adv Mater. 2010;11:014108.","journal-title":"Sci Technol Adv Mater"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/jps.22731","volume":"101","author":"ZK Nagy","year":"2012","unstructured":"Nagy ZK, Balogh A, Vajna B, Farkas A, Patyi G, Kramarics \u00c1, Marosi G. Comparison of electrospun and extruded Soluplus\u00ae-based solid dosage forms of improved dissolution. J Pharm Sci. 2012;101:322\u201332.","journal-title":"J Pharm Sci"},{"key":"1995_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0065-2156(07)41002-X","volume":"41","author":"D Reneker","year":"2007","unstructured":"Reneker D, Yarin A, Zussman E, Xu H. Electrospinning of nanofibers from polymer solutions and melts. Adv Appl Mech. 2007;41:43\u2013346.","journal-title":"Adv Appl Mech"},{"key":"1995_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0168-3659(02)00041-X","volume":"81","author":"R Kenawy el","year":"2002","unstructured":"Kenawy el R, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Controlled Release: Official J Controlled Release Soc. 2002;81:57\u201364.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"key":"1995_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.polymdegradstab.2018.05.018","volume":"154","author":"RA Rebia","year":"2018","unstructured":"Rebia RA, Rozet S, Tamada Y, Tanaka T. Biodegradable PHBH\/PVA blend nanofibers: fabrication, characterization, in vitro degradation, and in vitro biocompatibility. Polym Degrad Stab. 2018;154:124\u201336.","journal-title":"Polym Degrad Stab"},{"key":"1995_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/03639045.2025.2469140","volume":"51","author":"S Khaled","year":"2025","unstructured":"Khaled S, Mady O, Hedaya A, Abdine N, Haggag Y. Enhanced intestinal permeation of novel sulpiride electrospun nanofibers: formulation, optimization, and ex vivo evaluation of drug absorption. Drug Dev Ind Pharm. 2025;51:295\u2013308.","journal-title":"Drug Dev Ind Pharm"},{"key":"1995_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jconrel.2015.09.008","volume":"220","author":"S-F Chou","year":"2015","unstructured":"Chou S-F, Carson D, Woodrow KA. Current strategies for sustaining drug release from electrospun nanofibers. J Controlled Release. 2015;220:584\u201391.","journal-title":"J Controlled Release"},{"key":"1995_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1080\/10837450.2025.2517709","volume":"30","author":"OY Mady","year":"2025","unstructured":"Mady OY, Khaled S, Hedaya AA, Abdine N, Haggag Y. Formulation and characterization of novel oral pH-sensitive electrospun nanofibers for boosting dissolution and penetration of model class IV drug. Pharm Dev Technol. 2025;30:712\u201327.","journal-title":"Pharm Dev Technol"},{"key":"1995_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijpharm.2011.01.058","volume":"408","author":"X Shen","year":"2011","unstructured":"Shen X, Yu D, Zhu L, Branford-White C, White K, Chatterton NP. Electrospun diclofenac sodium loaded Eudragit\u00ae L 100\u201355 nanofibers for colon-targeted drug delivery. Int J Pharm. 2011;408:200\u20137.","journal-title":"Int J Pharm"},{"key":"1995_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ijpharm.2015.09.044","volume":"495","author":"UE Illangakoon","year":"2015","unstructured":"Illangakoon UE, Yu D-G, Ahmad BS, Chatterton NP, Williams GR. 5-fluorouracil loaded eudragit fibers prepared by electrospinning. Int J Pharm. 2015;495:895\u2013902.","journal-title":"Int J Pharm"},{"key":"1995_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/pj.2009.340","volume":"42","author":"J-C Park","year":"2010","unstructured":"Park J-C, Ito T, Kim K-O, Kim K-W, Kim B-S, Khil M-S, Kim H-Y, Kim I-S. Electrospun poly (vinyl alcohol) nanofibers: effects of degree of hydrolysis and enhanced water stability. Polym J. 2010;42:273\u20136.","journal-title":"Polym J"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3109\/03639045.2015.1088864","volume":"42","author":"HG Patil","year":"2016","unstructured":"Patil HG, Tiwari RV, Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42:906\u201315.","journal-title":"Drug Dev Ind Pharm"},{"key":"1995_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jsps.2020.01.005","volume":"28","author":"GM Zayed","year":"2020","unstructured":"Zayed GM, Rasoul SA-E, Ibrahim MA, Saddik MS, Alshora DH. In vitro and in vivo characterization of domperidone-loaded fast dissolving buccal films. Saudi Pharm J. 2020;28:266\u201373.","journal-title":"Saudi Pharm J"},{"key":"1995_CR16","doi-asserted-by":"publisher","first-page":"105645","DOI":"10.1016\/j.jddst.2024.105645","volume":"95","author":"S Ardalkar","year":"2024","unstructured":"Ardalkar S, Mathure D, Pawar A, Awasthi R. Formulation and optimization of electrospun nanofiber films for ultrafast delivery of domperidone: in vitro and in-vivo characterization. J Drug Deliv Sci Technol. 2024;95:105645.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1995_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/cpdd.43","volume":"3","author":"SA Helmy","year":"2014","unstructured":"Helmy SA, El HM, Bedaiwy. Pharmacokinetics and comparative bioavailability of domperidone suspension and tablet formulations in healthy adult subjects. Clin Pharmacol Drug Dev. 2014;3:126\u201331.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1995_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18433\/J3MK72","volume":"20","author":"BL Athukuri","year":"2017","unstructured":"Athukuri BL, Neerati P. Enhanced oral bioavailability of domperidone with piperine in male Wistar rats: involvement of CYP3A1 and P-gp inhibition. J Pharm Pharm Sci. 2017;20:28\u201337.","journal-title":"J Pharm Pharm Sci"},{"key":"1995_CR19","first-page":"152","volume":"2","author":"T Reena","year":"2012","unstructured":"Reena T, Vandana D. Enhancement of solubility and dissoultion rate of domperidone using cogrinding and kneading technique. J Drug Deliv Th. 2012;2:152\u20138.","journal-title":"J Drug Deliv Th"},{"key":"1995_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/2230-973X.143116","volume":"4","author":"DM Patel","year":"2014","unstructured":"Patel DM, Patel SP, Patel CN. Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion. Int J Pharm Invest. 2014;4:174.","journal-title":"Int J Pharm Invest"},{"key":"1995_CR21","first-page":"25","volume":"3","author":"K Patel","year":"2011","unstructured":"Patel K, Prasad K, Bajpai M. Enhancement of dissolution rate of domperidone using melt granulation technique. Pharm Lett. 2011;3:25\u201333.","journal-title":"Pharm Lett"},{"key":"1995_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-3659(99)00177-7","volume":"63","author":"M Nagarsenker","year":"2000","unstructured":"Nagarsenker M, Garad S, Ramprakash G. Design, optimization and evaluation of domperidone coevaporates. J Controlled Release. 2000;63:31\u20139.","journal-title":"J Controlled Release"},{"key":"1995_CR23","first-page":"23","volume-title":"Formulation and in vitro characterization of Domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers","author":"R Thatipamula","year":"2011","unstructured":"Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru: journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2011;19:23\u201332."},{"key":"1995_CR24","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1208\/s12249-018-0987-2","volume":"19","author":"GA Shazly","year":"2018","unstructured":"Shazly GA, Alshehri S, Ibrahim MA, Tawfeek HM, Razik JA, Hassan YA, Shakeel F. Development of domperidone solid lipid nanoparticles: in vitro and in vivo characterization. AAPS PharmSciTech. 2018;19:1712\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"1995_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13346-018-00596-w","volume":"9","author":"ST Ndlovu","year":"2019","unstructured":"Ndlovu ST, Ullah N, Khan S, Ramharack P, Soliman M, de Matas M, Shahid M, Sohail M, Imran M, Shah SWA, Hussain Z. Domperidone nanocrystals with boosted oral bioavailability: fabrication, evaluation and molecular insight into the polymer-domperidone nanocrystal interaction. Drug Delivery Translational Res. 2019;9:284\u201397.","journal-title":"Drug Delivery Translational Res"},{"key":"1995_CR26","doi-asserted-by":"publisher","first-page":"055104","DOI":"10.1088\/0957-4484\/20\/5\/055104","volume":"20","author":"D-G Yu","year":"2009","unstructured":"Yu D-G, Shen X-X, Branford-White C, White K, Zhu L-M, Bligh SA. Oral fast-dissolving drug delivery membranes prepared from electrospun polyvinylpyrrolidone ultrafine fibers. Nanotechnology. 2009;20:055104.","journal-title":"Nanotechnology"},{"key":"1995_CR27","doi-asserted-by":"publisher","first-page":"29037","DOI":"10.1021\/acsomega.5c01101","volume":"10","author":"S \u00d6zer","year":"2025","unstructured":"\u00d6zer S, Aky\u0131l E, Arslan R, Ar\u0131 NS. Development of nanofiber patch formulation containing rutin hydrate, in vitro and in vivo evaluation. ACS Omega. 2025;10:29037\u201358.","journal-title":"ACS Omega"},{"key":"1995_CR28","first-page":"53","volume":"7","author":"M Alim","year":"2015","unstructured":"Alim M, Karna S, Chaturvedi S, Agrawal VK. Validated UV spectrophotometric method for estimation of domperidone for dissolution study. Der Pharmacia Lettre. 2015;7:53\u20138.","journal-title":"Der Pharmacia Lettre"},{"key":"1995_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1177\/0271678X20943823","volume":"40","author":"N Percie du","year":"2020","unstructured":"Percie du N, Sert V, Hurst A, Ahluwalia S, Alam MT, Avey M, Baker WJ, Browne A, Clark IC, Cuthill U, Dirnagl. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metabolism. 2020;40:1769\u201377.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"1995_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4103\/jpbs.jpbs_860_21","volume":"15","author":"MM Azeemuddin","year":"2023","unstructured":"Azeemuddin MM, Narendra MM, Mallappa O, Anturlikar SD, Baig MR, Rafiq M. Herbal combination \u2018HAGE-101912\u2019Ameliorates gastroesophageal reflux disease in rats. J Pharm Bioallied Sci. 2023;15:212\u20138.","journal-title":"J Pharm Bioallied Sci"},{"key":"1995_CR31","doi-asserted-by":"crossref","unstructured":"Khodir SA, Sweed E, Motawea SM, Al-Gholam MA, Elnaidany SS, Dayer MZS, Ameen O. Diacerein and myo-inositol alleviate letrozole-induced PCOS via modulation of HMGB1, SIRT1, and NF-kB: a comparative study. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2024:1\u201319.","DOI":"10.1007\/s00210-024-03497-7"},{"key":"1995_CR32","unstructured":"Kalluri L, Satpathy M, Duan Y. Effect of electrospinning parameters on the fiber diameter and morphology of PLGA nanofibers. Dent Oral Biology Craniofac Res. 2021;4."},{"key":"1995_CR33","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00289-016-1620-8","volume":"73","author":"H Itoh","year":"2016","unstructured":"Itoh H, Li Y, Chan KHK, Kotaki M. Morphology and mechanical properties of PVA nanofibers spun by free surface electrospinning. Polym Bull. 2016;73:2761\u201377.","journal-title":"Polym Bull"},{"key":"1995_CR34","doi-asserted-by":"crossref","unstructured":"Rajeev M, Helms CC. A study of the relationship between polymer solution entanglement and electrospun PCL fiber mechanics. Volume 15. Polymers; 2023. p. 4555.","DOI":"10.3390\/polym15234555"},{"key":"1995_CR35","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1166\/jbn.2014.1885","volume":"10","author":"N Goonoo","year":"2014","unstructured":"Goonoo N, Bhaw-Luximon A, Jhurry D. Drug loading and release from electrospun biodegradable nanofibers. J Biomed Nanotechnol. 2014;10:2173\u201399.","journal-title":"J Biomed Nanotechnol"},{"key":"1995_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.msec.2008.10.037","volume":"29","author":"V Beachley","year":"2009","unstructured":"Beachley V, Wen X. Effect of electrospinning parameters on the nanofiber diameter and length. Mater Sci Engineering: C. 2009;29:663\u20138.","journal-title":"Mater Sci Engineering: C"},{"key":"1995_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s11671-019-3148-y","volume":"14","author":"Z Liu","year":"2019","unstructured":"Liu Z, Ju K, Wang Z, Li W, Ke H, He J. Electrospun jets number and nanofiber morphology effected by voltage value: numerical simulation and experimental verification. Nanoscale Res Lett. 2019;14:310.","journal-title":"Nanoscale Res Lett"},{"key":"1995_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1515\/dmpt-2015-0004","volume":"30","author":"A Devandla","year":"2015","unstructured":"Devandla A, Yamsani SK, Yamsani MR. Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers. Drug Metabolism Personalized Therapy. 2015;30:257\u201361.","journal-title":"Drug Metabolism Personalized Therapy"},{"key":"1995_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/dmdi-2014-0013","volume":"29","author":"SK Yamsani","year":"2014","unstructured":"Yamsani SK, Yamsani MR. Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers. Drug Metab Drug Interact. 2014;29:261\u20137.","journal-title":"Drug Metab Drug Interact"},{"key":"1995_CR40","first-page":"e1859","volume":"15","author":"S Pattnaik","year":"2023","unstructured":"Pattnaik S, Swain K, Ramakrishna S. Optimal delivery of poorly soluble drugs using electrospun nanofiber technology: challenges, state of the art, and future directions. Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol. 2023;15:e1859.","journal-title":"Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol"},{"key":"1995_CR41","doi-asserted-by":"publisher","first-page":"120301","DOI":"10.1016\/j.lfs.2022.120301","volume":"291","author":"KU Khan","year":"2022","unstructured":"Khan KU, Minhas MU, Badshah SF, Suhail M, Ahmad A, Ijaz S. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs. Life Sci. 2022;291:120301.","journal-title":"Life Sci"},{"key":"1995_CR42","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2174\/1567201820666230214091509","volume":"21","author":"N Okur","year":"2024","unstructured":"Okur N, \u00c7a\u011flar E, Kaynak MS, Diril M, \u00d6zcan S, Karasulu HY. Enhancing oral bioavailability of domperidone maleate: formulation, in vitro permeability evaluation in-caco-2 cell monolayers and in situ rat intestinal permeability studies. Curr Drug Deliv. 2024;21:1010\u201323.","journal-title":"Curr Drug Deliv"},{"key":"1995_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/pdi.1728","volume":"29","author":"J Lang","year":"2012","unstructured":"Lang J, Reed E, Fisher M, McKay G. Domperidone, practical diabetes. 2012;29:383\u2013a384.","journal-title":"Domperidone Practical Diabetes"},{"key":"1995_CR44","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","volume":"102","author":"SC Reddymasu","year":"2007","unstructured":"Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036\u201345.","journal-title":"Am J Gastroenterol"},{"key":"1995_CR45","doi-asserted-by":"crossref","unstructured":"Ng LH, Ling JKU, Hadinoto K. Formulation strategies to improve the stability and handling of oral solid dosage forms of highly hygroscopic pharmaceuticals and nutraceuticals. Pharmaceutics. 2022:14.","DOI":"10.3390\/pharmaceutics14102015"},{"key":"1995_CR46","doi-asserted-by":"crossref","unstructured":"Iyer R, Petrovska Jovanovska V, Berginc K, Jakli\u010d M, Fabiani F, Harlacher C, Huzjak T, Sanchez-Felix MV. Amorphous solid dispersions (ASDs): the influence of material properties, manufacturing processes and analytical technologies in drug product development. Pharmaceutics. 2021:13.","DOI":"10.3390\/pharmaceutics13101682"},{"key":"1995_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.xphs.2022.10.020","volume":"112","author":"HS Purohit","year":"2023","unstructured":"Purohit HS, Zhang GGZ, Gao Y. Detecting crystallinity in amorphous solid dispersions using dissolution testing: considerations on properties of drug substance, drug product, and selection of dissolution media. J Pharm Sci. 2023;112:290\u2013303.","journal-title":"J Pharm Sci"},{"key":"1995_CR48","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1080\/17425247.2020.1813714","volume":"17","author":"Y Haggag","year":"2020","unstructured":"Haggag Y, Abu Ras B, El-Tanani Y, Tambuwala MM, McCarron P, Isreb M, El-Tanani M. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 2020;17:1655\u201369.","journal-title":"Expert Opin Drug Deliv"},{"key":"1995_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijpharm.2017.02.006","volume":"521","author":"YA Haggag","year":"2017","unstructured":"Haggag YA, Matchett KB, Dakir El H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA. Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. Int J Pharm. 2017;521:40\u201353.","journal-title":"Int J Pharm"},{"key":"1995_CR50","doi-asserted-by":"publisher","first-page":"113649","DOI":"10.1016\/j.biopha.2022.113649","volume":"155","author":"R Khan","year":"2022","unstructured":"Khan R, Arshad F, Hassan IU, Naikoo GA, Pedram MZ, Zedegan MS, Pourfarzad H, Aljabali AA, Serrano-Aroca \u00c1, Haggag Y. Advances in nanomaterial-based immunosensors for prostate cancer screening. Biomed Pharmacother. 2022;155:113649.","journal-title":"Biomed Pharmacother"},{"key":"1995_CR51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0149-2918(98)80054-4","volume":"20","author":"D Silvers","year":"1998","unstructured":"Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 study group. Clin Ther. 1998;20:438\u201353.","journal-title":"Clin Ther"},{"key":"1995_CR52","doi-asserted-by":"publisher","first-page":"119632","DOI":"10.1016\/j.lfs.2021.119632","volume":"278","author":"SH Shahcheraghi","year":"2021","unstructured":"Shahcheraghi SH, Aljabali AAA, Al Zoubi MS, Mishra V, Charbe NB, Haggag YA, Shrivastava G, Almutary AG, Alnuqaydan AM, Barh D, Dua K, Chellappan DK, Gupta G, Lotfi M, Serrano-Aroca \u00c1, Bahar B, Mishra YK, Takayama K, Panda PK, Bakshi HA, Tambuwala MM. Overview of key molecular and pharmacological targets for diabetes and associated diseases. Life Sci. 2021;278:119632.","journal-title":"Life Sci"},{"key":"1995_CR53","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1212\/WNL.96.15_supplement.2313","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch MW, Sage K, Kaur S, Kim J, Cerchiaro G, Yong VW, Cutter GR, Metz LM. Repurposing domperidone in secondary progressive multiple sclerosis. Neurology. 2021;96:e2313\u201322.","journal-title":"Neurology"},{"key":"1995_CR54","doi-asserted-by":"publisher","first-page":"117793222513650","DOI":"10.1177\/11779322251365019","volume":"19","author":"P C","year":"2025","unstructured":"C P, Kurmi HSSPC, Patra BR, Esther VA, Yadav CK, Biradar MS, Thapa S. Repurposing terfenadine and domperidone for inhibition of apoptotic gene association in colorectal cancer: a system pharmacology approach integrated with molecular docking, MD simulations, and post-MD simulation analysis. Bioinform Biol Insights. 2025;19:11779322251365019.","journal-title":"Bioinform Biol Insights"},{"key":"1995_CR55","doi-asserted-by":"publisher","first-page":"110468","DOI":"10.1016\/j.mehy.2020.110468","volume":"146","author":"NE El-Ashmawy","year":"2020","unstructured":"El-Ashmawy NE, Lashin AA, Okasha KM, Abo Kamer AM, Mostafa TM, El-Aasr M, Goda AE, Haggag YA, Tawfik HO. Abo-Saif, the plausible mechanisms of tramadol for treatment of COVID-19. Med Hypotheses. 2020;146:110468.","journal-title":"Med Hypotheses"},{"key":"1995_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000354579","volume":"92","author":"Y Jang","year":"2013","unstructured":"Jang Y, Kim T-K, Shim W-S. Naringin exhibits in vivo prokinetic activity via activation of ghrelin receptor in gastrointestinal motility dysfunction rats. Pharmacology. 2013;92:191\u20137.","journal-title":"Pharmacology"},{"key":"1995_CR57","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2460\/ajvr.74.8.1103","volume":"74","author":"JE Nieto","year":"2013","unstructured":"Nieto JE, Maher O, Stanley SD, Larson R, Snyder JR. In vivo and in vitro evaluation of the effects of domperidone on the gastrointestinal tract of healthy horses. Am J Vet Res. 2013;74:1103\u201310.","journal-title":"Am J Vet Res"},{"key":"1995_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/MAJ.0000000000000439","volume":"349","author":"A Ortiz","year":"2015","unstructured":"Ortiz A, Cooper CJ, Gomez Y, Sarosiek I, McCallum RW, Alvarez A. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349:421\u20134.","journal-title":"Am J Med Sci"},{"key":"1995_CR59","first-page":"e13","volume":"77","author":"MG Puoti","year":"2023","unstructured":"Puoti MG, Assa A, Benninga M, Broekaert IJ, Carpi FJM, Deganello Saccomani M, Dolinsek J, Homan M, Mas E, Miele E, Tzivinikos C, Thomson M, Borrelli O. Drugs in focus: domperidone. J Pediatr Gastroenterol Nutr. 2023;77:e13\u201322.","journal-title":"Drugs Focus: Domperidone J Pediatr Gastroenterol Nutr"},{"key":"1995_CR60","unstructured":"Hancock BC, Moss G, Goldfarb D. Pharmaceutical excipients, hypromellose acetate succinate http:\/\/www.medicinescomplete.com\/(Sist oppdatert: 9, (2021)."},{"key":"1995_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/08982104.2021.1918153","volume":"32","author":"N Islam","year":"2022","unstructured":"Islam N, Irfan M, Hussain T, Mushtaq M, Khan IU, Yousaf AM, Ghori MU, Shahzad Y. Piperine phytosomes for bioavailability enhancement of domperidone. J Liposome Res. 2022;32:172\u201380.","journal-title":"J Liposome Res"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01995-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:03:28Z","timestamp":1779113008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01995-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01995-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"(TP\/RE\/1\/25 P-01 is the ethical approval code).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The corresponding author consents to publication submission on behalf of all coauthors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}